Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

Flonza Isa,Eduardo Forleo-Neto,Jonathan Meyer, Wenjun Zheng,Scott Rasmussen,Danielle Armas, Masaru Oshita,Cynthia Brinson, Steven Folkerth,Lori Faria,Ingeborg Heirman,Neena Sarkar,Bret J. Musser,Shikha Bansal,Meagan P. O'Brien,Kenneth C. Turner,Samit Ganguly,Adnan Mahmood,Ajla Dupljak,Andrea T. Hooper

International Journal of Infectious Diseases（2022）

Cited 12|Views9
No score
Abstract
•Phase 1 study assessed monthly casirivimab+imdevimab (CAS+IMD) in uninfected adults•Repeat monthly CAS+IMD (1200 mg subcutaneously [SC]) was well-tolerated, with low immunogenicity•CAS+IMD (1200 mg SC) showed a substantial risk reduction in COVID-19 occurrence
More
Translated text
Key words
COVID-19,SARS-CoV-2,Monoclonal antibody,Casirivimab,Imdevimab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined